Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing antibiotic selection in treating COPD exacerbations.

Attiya Siddiqi1, Sanjay Sethi

  • 1Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine,Veterans Affairs Western New York Health Care System, Buffalo, NY 14125, USA.

International Journal of Chronic Obstructive Pulmonary Disease
|May 21, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of patients with COPD before and after initiation of treatment with budesonide/glycopyrrolate/formoterol fumarate: Results from the US ARCTOS study.

Respiratory medicine·2026
Same author

The natural human adaptive IgG-specific immune response is skewed towards non-protective tail domains of DNABII proteins.

Frontiers in immunology·2026
Same author

Effect of a self-directed lifestyle-based weight management program among patients with comorbid COPD and sleep apnea: a secondary analysis of the INSIGHT COPD trial.

Annals of the American Thoracic Society·2025
Same author

Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL.

International journal of chronic obstructive pulmonary disease·2025
Same author

Leveraging dynamic stability to infer regulation in protein-protein interaction networks: A study of infectious vulnerability in COPD.

PloS one·2025
Same author

Progression from GOLD A/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapy.

BMC pulmonary medicine·2025
Same journal

Real-Life Effectiveness of Aclidinium/Formoterol on COPD Control: The REDACT Observational Study.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Cardiopulmonary Exercise Testing and Quantitative Chest CT in COPD: The Stronger Association of Emphysema Over Airway Thickness with Functional Impairment.

International journal of chronic obstructive pulmonary disease·2026
Same journal

A Nomogram for Predicting Successful Weaning from Invasive Mechanical Ventilation Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Complicated by Respiratory Failure.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Diagnostic Value of miR-192-5p in the Progression of Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Heart Disease.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Association Between Chronic Obstructive Pulmonary Disease and Survival in Patients with Lung Cancer: A Nationwide Cohort Study.

International journal of chronic obstructive pulmonary disease·2026
See all related articles

Antibiotic treatment offers clinical benefits for moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations. Risk stratification guides antibiotic selection, reserving broad-spectrum drugs for high-risk patients to improve outcomes.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Understanding of chronic obstructive pulmonary disease (COPD) exacerbations has advanced significantly.
  • Bacterial infections are increasingly recognized as a direct cause of COPD exacerbations.
  • Antibiotic therapy has demonstrated clinical benefits in managing moderate to severe COPD exacerbations.

Purpose of the Study:

  • To review the current evidence on antibiotic use in COPD exacerbations.
  • To explore the role of risk stratification in optimizing antibiotic selection.
  • To address concerns regarding antibiotic resistance and judicious antibiotic use.

Main Methods:

  • Systematic review of placebo-controlled antibiotic trials and observational studies.

Related Experiment Videos

  • Analysis of clinical outcomes in relation to antibiotic choice and patient risk factors.
  • Evaluation of methodological limitations in existing antibiotic comparison trials.

    • Main Results:

    • Antibiotics provide significant clinical benefits for moderate and severe COPD exacerbations.
    • Previous trials often lacked the power to detect differences between antibiotics due to methodological limitations.
    • Certain clinical characteristics are associated with treatment failure or relapse, suggesting the need for risk stratification.
    • Emerging evidence suggests differences in outcomes with specific antibiotics when using non-traditional endpoints.

    Conclusions:

    • Risk stratification is a promising approach for tailoring antibiotic selection in COPD exacerbations.
    • Differentiating between low-risk and high-risk patients may optimize treatment and reserve broad-spectrum antibiotics.
    • This strategy addresses disease heterogeneity, antibiotic resistance, and promotes judicious antibiotic use, although prospective validation is needed.